173 related articles for article (PubMed ID: 12014019)
1. [Comparative evaluation of serum HCV RNA by Roche Monitor Assay. Versions 1.0 and 2.0; as a predictive marker of subsequent response to IFN therapy].
Takenokuchi M; Yasuda C; Nakamachi Y; Mukai M; Yoon S; Kondoh S; Kumagai S
Rinsho Byori; 2002 Apr; 50(4):392-7. PubMed ID: 12014019
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
Kawai S; Yokosuka O; Imazeki F; Saisho H; Mizuno C
J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
[TBL] [Abstract][Full Text] [Related]
3. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.
Kurosaki M; Enomoto N; Murakami T; Sakuma I; Asahina Y; Yamamoto C; Ikeda T; Tozuka S; Izumi N; Marumo F; Sato C
Hepatology; 1997 Mar; 25(3):750-3. PubMed ID: 9049230
[TBL] [Abstract][Full Text] [Related]
4. Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon.
Trabaud MA; Bailly F; Si-Ahmed SN; Chevallier P; Sepetjan M; Colucci G; Trépo C
J Med Virol; 1997 May; 52(1):105-12. PubMed ID: 9131466
[TBL] [Abstract][Full Text] [Related]
5. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C.
Karino Y; Toyota J; Sugawara M; Higashino K; Sato T; Ohmura T; Suga T; Okuuchi Y; Matsushima T
Am J Gastroenterol; 1997 Jan; 92(1):61-5. PubMed ID: 8995939
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays.
Lunel F; Cresta P; Vitour D; Payan C; Dumont B; Frangeul L; Reboul D; Brault C; Piette JC; Huraux JM
Hepatology; 1999 Feb; 29(2):528-35. PubMed ID: 9918931
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of serum levels of HCV RNA in early phase of IFN therapy; as a predictive marker of subsequent response.
Yamakawa Y; Sata M; Suzuki H; Tanaka K; Tanaka E; Noguchi S; Ono K; Tanikawa K
Hepatogastroenterology; 1998; 45(19):133-6. PubMed ID: 9496502
[TBL] [Abstract][Full Text] [Related]
9. [Clinical benefit of HCV core antigen assay in patients receiving interferon and ribavirin combination therapy].
Higashimoto M; Takahashi M; Jokyu R; Saito H
Rinsho Byori; 2006 Feb; 54(2):111-5. PubMed ID: 16548229
[TBL] [Abstract][Full Text] [Related]
10. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
[TBL] [Abstract][Full Text] [Related]
11. Differences in viral kinetics between genotypes 1 and 2 of hepatitis C virus after single administration of standard interferon-alpha.
Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Takagi M; Nakano S; Arakawa T; Fujimori M
J Med Virol; 2009 Aug; 81(8):1354-62. PubMed ID: 19551828
[TBL] [Abstract][Full Text] [Related]
12. Hepatic iron stainings in chronic hepatitis C patients with low HCV RNA levels: a predictive marker for IFN therapy.
Akiyoshi F; Sata M; Uchimura Y; Suzuki H; Tanikawa K
Am J Gastroenterol; 1997 Sep; 92(9):1463-6. PubMed ID: 9317063
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load.
Hofer H; Watkins-Riedel T; Janata O; Penner E; Holzmann H; Steindl-Munda P; Gangl A; Ferenci P
Hepatology; 2003 Jan; 37(1):60-4. PubMed ID: 12500189
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
[TBL] [Abstract][Full Text] [Related]
15. Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis.
Watkins-Riedel T; Ferenci P; Steindl-Munda P; Gschwantler M; Mueller C; Woegerbauer M
Clin Infect Dis; 2004 Dec; 39(12):1754-60. PubMed ID: 15578395
[TBL] [Abstract][Full Text] [Related]
16. Broad differences between the COBAS ampliprep total nucleic acid isolation-COBAS TaqMan 48 hepatitis C virus (HCV) and COBAS HCV monitor v2.0 assays for quantification of serum HCV RNA of non-1 genotypes.
Colson P; Motte A; Tamalet C
J Clin Microbiol; 2006 Apr; 44(4):1602-3. PubMed ID: 16597910
[No Abstract] [Full Text] [Related]
17. Association with 5'-untranslated region and response to interferon in chronic hepatitis C.
Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
Hepatogastroenterology; 2007; 54(75):854-7. PubMed ID: 17591078
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of the COBAS Ampliprep/COBAS TaqMan for HCV RNA quantitation in comparison with the branched-DNA assay.
Pittaluga F; Allice T; Abate ML; Ciancio A; Cerutti F; Varetto S; Colucci G; Smedile A; Ghisetti V
J Med Virol; 2008 Feb; 80(2):254-60. PubMed ID: 18098148
[TBL] [Abstract][Full Text] [Related]
19. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
[TBL] [Abstract][Full Text] [Related]
20. Management strategies using pharmacogenomics in patients with severe HCV-1b infection: a decision analysis.
Moriguchi H; Uemura T; Kobayashi M; Chung RT; Sato C
Hepatology; 2002 Jul; 36(1):177-85. PubMed ID: 12085363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
